Home » Stocks » CVM

Cel-Sci Corporation (CVM)

Stock Price: $12.94 USD 0.45 (3.60%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 499.80M
Revenue (ttm) 663,927
Net Income (ttm) -29.58M
Shares Out 38.62M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $12.94
Previous Close $12.49
Change ($) 0.45
Change (%) 3.60%
Day's Open 12.50
Day's Range 12.50 - 12.94
Day's Volume 203,889
52-Week Range 6.35 - 18.00

More Stats

Market Cap 499.80M
Enterprise Value 492.15M
Earnings Date (est) Dec 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.62M
Float 36.96M
EPS (basic) -0.81
EPS (diluted) -0.83
FCF / Share -0.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.33M
Short Ratio 20.42
Short % of Float 27.96%
Beta 2.42
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 752.79
PB Ratio 24.80
Revenue 663,927
Operating Income -25.96M
Net Income -29.58M
Free Cash Flow -17.11M
Net Cash 7.65M
Net Cash / Share 0.20
Gross Margin -2,010.18%
Operating Margin -3,909.81%
Profit Margin -4,454.90%
FCF Margin -2,577.67%
ROA -46.11%
ROE -293.41%
ROIC -101.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $12.94
Target: 19.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-2.13%693.18%-75.79%-56.64%148.98%65.45%-37.32%-73.37%523.71%-
Gross Profit0.540.550.070.290.660.
Operating Income-20.12-16.70-21.34-23.65-32.39-25.67-19.87-17.24-17.99-18.56
Net Income-22.13-31.85-14.43-11.51-34.69-27.35-9.23-15.48-25.7110.48
Shares Outstanding31.1717.007.894.873.302.351.211.010.830.81
Earnings Per Share-0.71-1.87-1.91-2.37-10.51-12.21-16.50-19.50-37.25-15.00
Operating Cash Flow-16.32-13.39-13.79-23.08-23.83-22.93-13.55-12.19-22.56-12.80
Capital Expenditures-0.18--0.01-0.03-0.07-0.10-0.10-0.05-0.22-0.53
Free Cash Flow-16.50-13.39-13.80-23.11-23.91-23.03-13.65-12.24-22.77-13.33
Cash & Equivalents10.1211.984.044.747.7010.632.115.615.9326.59
Total Debt13.5113.3814.2113.0127.571.
Net Cash / Debt-3.39-1.40-10.17-8.27-19.889.510.98-2.48-0.1725.49
Book Value5.13--3.34-0.68-4.7610.446.707.039.0827.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cel-Sci Corporation
Country United States
CEO Geert R. Kersten

Stock Information

Ticker Symbol CVM
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: CVM
IPO Date January 1, 1987


CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.